Omnicell (OMCL) 10-Q 8 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 30, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	000-33043
Entity Registrant Name	OMNICELL, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3166458
Entity Address, Address Line One	4220 North Freeway
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76137
City Area Code	877
Local Phone Number	415-9990
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OMCL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,316,825
Entity Central Index Key	0000926326
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 570,628	$ 467,972
Accounts receivable and unbilled receivables, net of allowances of $7,103 and $5,564, respectively	251,764	252,025
Inventories	95,059	110,099
Prepaid expenses	28,884	25,966
Other current assets	64,927	71,509
Total current assets	1,011,262	927,571
Property and equipment, net	111,744	108,601
Long-term investment in sales-type leases, net	50,575	42,954
Operating lease right-of-use assets	25,312	24,988
Goodwill	737,169	735,810
Intangible assets, net	193,969	211,173
Long-term deferred tax assets	42,093	32,901
Prepaid commissions	49,730	52,414
Other long-term assets	81,734	90,466
Total assets	2,303,588	2,226,878
Current liabilities:
Accounts payable	47,810	45,028
Accrued compensation	45,090	51,754
Accrued liabilities	144,253	149,276
Deferred revenues	152,367	121,734
Convertible senior notes, net	571,997	0
Total current liabilities	961,517	367,792
Long-term deferred revenues	69,811	58,622
Long-term deferred tax liabilities	1,411	1,620
Long-term operating lease liabilities	31,524	33,910
Other long-term liabilities	7,997	6,318
Convertible senior notes, net	0	569,662
Total liabilities	1,072,260	1,037,924
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 56,596 and 55,822 shares issued; 46,313 and 45,539 shares outstanding, respectively	57	56
Treasury stock at cost, 10,283 shares outstanding, respectively	(290,319)	(290,319)
Additional paid-in capital	1,164,847	1,122,292
Retained earnings	367,046	370,357
Accumulated other comprehensive loss	(10,303)	(13,432)
Total stockholders’ equity	1,231,328	1,188,954
Total liabilities and stockholders’ equity	$ 2,303,588	$ 2,226,878

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for credit losses on accounts receivable and unbilled receivables	$ 7,103	$ 5,564
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000	100,000
Common stock, shares issued (in shares)	56,596	55,822
Common stock, shares outstanding (in shares)	46,313	45,539
Treasury stock, shares outstanding (in shares)	10,283	10,283

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 282,420	$ 298,663	$ 805,359	$ 888,265
Cost of revenues	160,152	166,699	476,117	496,829
Gross profit	122,268	131,964	329,242	391,436
Operating expenses:
Research and development	21,214	24,281	64,372	70,296
Selling, general, and administrative	94,490	103,971	276,929	332,643
Total operating expenses	115,704	128,252	341,301	402,939
Income (loss) from operations	6,564	3,712	(12,059)	(11,503)
Interest and other income (expense), net	5,063	3,670	14,052	9,912
Income (loss) before income taxes	11,627	7,382	1,993	(1,591)
Provision for income taxes	2,997	1,829	5,304	4,405
Net income (loss)	$ 8,630	$ 5,553	$ (3,311)	$ (5,996)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.19	$ 0.12	$ (0.07)	$ (0.13)
Diluted (in dollars per share)	$ 0.19	$ 0.12	$ (0.07)	$ (0.13)
Weighted-average shares outstanding:
Basic (in shares)	46,153	45,333	45,947	45,117
Diluted (in shares)	46,427	45,595	45,947	45,117
Product revenues
Revenues	$ 158,361	$ 188,755	$ 448,236	$ 562,906
Cost of revenues	94,448	106,311	286,270	323,800
Service revenues
Revenues	124,059	109,908	357,123	325,359
Cost of revenues	$ 65,704	$ 60,388	$ 189,847	$ 173,029

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 8,630	$ 5,553	$ (3,311)	$ (5,996)
Other comprehensive income (loss):
Foreign currency translation adjustments	4,575	(2,953)	3,129	(42)
Other comprehensive income (loss)	4,575	(2,953)	3,129	(42)
Comprehensive income (loss)	$ 13,205	$ 2,600	$ (182)	$ (6,038)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2022		55,030
Beginning balance at Dec. 31, 2022	$ 1,130,137	$ 55	$ (290,319)	$ 1,046,760	$ 390,728	$ (17,087)
Balance at beginning of period (in shares) at Dec. 31, 2022			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(15,000)				(15,000)
Other comprehensive income (loss)	1,479					1,479
Share-based compensation	15,180			15,180
Issuance of common stock under employee stock plans (in shares)		322
Issuance of common stock under employee stock plans	12,114			12,114
Tax payments related to restricted stock units	(1,369)			(1,369)
Balance at end of period (in shares) at Mar. 31, 2023		55,352
Ending balance at Mar. 31, 2023	1,142,541	$ 55	$ (290,319)	1,072,685	375,728	(15,608)
Balance at end of period (in shares) at Mar. 31, 2023			(10,283)
Balance at beginning of period (in shares) at Dec. 31, 2022		55,030
Beginning balance at Dec. 31, 2022	1,130,137	$ 55	$ (290,319)	1,046,760	390,728	(17,087)
Balance at beginning of period (in shares) at Dec. 31, 2022			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(5,996)
Other comprehensive income (loss)	(42)
Balance at end of period (in shares) at Sep. 30, 2023		55,746
Ending balance at Sep. 30, 2023	1,187,436	$ 56	$ (290,319)	1,110,096	384,732	(17,129)
Balance at end of period (in shares) at Sep. 30, 2023			(10,283)
Balance at beginning of period (in shares) at Mar. 31, 2023		55,352
Beginning balance at Mar. 31, 2023	1,142,541	$ 55	$ (290,319)	1,072,685	375,728	(15,608)
Balance at beginning of period (in shares) at Mar. 31, 2023			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,451				3,451
Other comprehensive income (loss)	1,432					1,432
Share-based compensation	15,148			15,148
Issuance of common stock under employee stock plans (in shares)		136
Issuance of common stock under employee stock plans	3,089	$ 1		3,088
Tax payments related to restricted stock units	(2,096)			(2,096)
Balance at end of period (in shares) at Jun. 30, 2023		55,488
Ending balance at Jun. 30, 2023	1,163,565	$ 56	$ (290,319)	1,088,825	379,179	(14,176)
Balance at end of period (in shares) at Jun. 30, 2023			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	5,553				5,553
Other comprehensive income (loss)	(2,953)					(2,953)
Share-based compensation	16,104			16,104
Issuance of common stock under employee stock plans (in shares)		258
Issuance of common stock under employee stock plans	7,832			7,832
Tax payments related to restricted stock units	(2,665)			(2,665)
Balance at end of period (in shares) at Sep. 30, 2023		55,746
Ending balance at Sep. 30, 2023	$ 1,187,436	$ 56	$ (290,319)	1,110,096	384,732	(17,129)
Balance at end of period (in shares) at Sep. 30, 2023			(10,283)
Balance at beginning of period (in shares) at Dec. 31, 2023	45,539	55,822
Beginning balance at Dec. 31, 2023	$ 1,188,954	$ 56	$ (290,319)	1,122,292	370,357	(13,432)
Balance at beginning of period (in shares) at Dec. 31, 2023	(10,283)		(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (15,676)				(15,676)
Other comprehensive income (loss)	(1,399)					(1,399)
Share-based compensation	9,381			9,381
Issuance of common stock under employee stock plans (in shares)		385
Issuance of common stock under employee stock plans	8,042			8,042
Tax payments related to restricted stock units	(705)			(705)
Balance at end of period (in shares) at Mar. 31, 2024		56,207
Ending balance at Mar. 31, 2024	$ 1,188,597	$ 56	$ (290,319)	1,139,010	354,681	(14,831)
Balance at end of period (in shares) at Mar. 31, 2024			(10,283)
Balance at beginning of period (in shares) at Dec. 31, 2023	45,539	55,822
Beginning balance at Dec. 31, 2023	$ 1,188,954	$ 56	$ (290,319)	1,122,292	370,357	(13,432)
Balance at beginning of period (in shares) at Dec. 31, 2023	(10,283)		(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (3,311)
Other comprehensive income (loss)	$ 3,129
Balance at end of period (in shares) at Sep. 30, 2024	46,313	56,596
Ending balance at Sep. 30, 2024	$ 1,231,328	$ 57	$ (290,319)	1,164,847	367,046	(10,303)
Balance at end of period (in shares) at Sep. 30, 2024	(10,283)		(10,283)
Balance at beginning of period (in shares) at Mar. 31, 2024		56,207
Beginning balance at Mar. 31, 2024	$ 1,188,597	$ 56	$ (290,319)	1,139,010	354,681	(14,831)
Balance at beginning of period (in shares) at Mar. 31, 2024			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,735				3,735
Other comprehensive income (loss)	(47)					(47)
Share-based compensation	11,010			11,010
Issuance of common stock under employee stock plans (in shares)		70
Issuance of common stock under employee stock plans	99			99
Tax payments related to restricted stock units	(586)			(586)
Balance at end of period (in shares) at Jun. 30, 2024		56,277
Ending balance at Jun. 30, 2024	1,202,808	$ 56	$ (290,319)	1,149,533	358,416	(14,878)
Balance at end of period (in shares) at Jun. 30, 2024			(10,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,630				8,630
Other comprehensive income (loss)	4,575					4,575
Share-based compensation	12,569			12,569
Issuance of common stock under employee stock plans (in shares)		319
Issuance of common stock under employee stock plans	4,999	$ 1		4,998
Tax payments related to restricted stock units	$ (2,253)			(2,253)
Balance at end of period (in shares) at Sep. 30, 2024	46,313	56,596
Ending balance at Sep. 30, 2024	$ 1,231,328	$ 57	$ (290,319)	$ 1,164,847	$ 367,046	$ (10,303)
Balance at end of period (in shares) at Sep. 30, 2024	(10,283)		(10,283)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating Activities
Net loss	$ (3,311)	$ (5,996)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	62,266	65,596
Loss on disposal of assets	412	2,110
Share-based compensation expense	30,277	43,113
Deferred income taxes	(9,401)	(14,165)
Amortization of operating lease right-of-use assets	5,279	6,238
Impairment and abandonment of operating lease right-of-use assets related to facilities	0	7,815
Inventory write-down	5,393	0
Amortization of debt issuance costs	2,917	3,139
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	1,174	27,050
Inventories	10,038	31,690
Prepaid expenses	(2,918)	(857)
Other current assets	8,354	1,521
Investment in sales-type leases	(7,453)	(8,839)
Prepaid commissions	2,684	5,533
Other long-term assets	1,048	2,539
Accounts payable	2,945	(13,358)
Accrued compensation	(6,664)	(29,390)
Accrued liabilities	6,963	3,749
Deferred revenues	27,746	23,628
Operating lease liabilities	(8,021)	(8,145)
Other long-term liabilities	1,679	(291)
Net cash provided by operating activities	131,407	142,680
Investing Activities
External-use software development costs	(11,849)	(10,240)
Purchases of property and equipment	(27,376)	(32,404)
Net cash used in investing activities	(39,225)	(42,644)
Financing Activities
Proceeds from issuances under stock-based compensation plans	13,140	23,035
Employees’ taxes paid related to restricted stock units	(3,544)	(6,130)
Change in customer funds, net	(10,744)	(6,615)
Net cash provided by (used in) financing activities	(1,148)	10,290
Effect of exchange rate changes on cash and cash equivalents	879	(464)
Net increase in cash, cash equivalents, and restricted cash	91,913	109,862
Cash, cash equivalents, and restricted cash at beginning of period	500,979	352,835
Cash, cash equivalents, and restricted cash at end of period	592,892	462,697
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	570,628	446,840
Restricted cash included in other current assets	22,264	15,857
Cash, cash equivalents, and restricted cash at end of period	592,892	462,697
Supplemental disclosure of non-cash investing activities
Unpaid purchases of property and equipment	$ 432	$ 642

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2024 and December 31, 2023, the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 28, 2024. The Company’s results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024, or for any future period. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2024, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. Recently Adopted Authoritative Guidance There was no recently adopted authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date. Recently Issued Authoritative Guidance In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its balance sheets, statements of operations, or statements of cash flows, as the anticipated changes will be the inclusion of additional disclosures related to the Company’s single reportable segment. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements. In March 2024, the SEC issued final rules under SEC Release No. 33-11275, “The Enhancement and Standardization of Climate-Related Disclosures for Investors,” to require registrants to disclose certain climate-related information, including Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics, if material, in registration statements and annual reports. In April 2024, the SEC voluntarily stayed its climate disclosure rules as a result of pending legal challenges to facilitate an orderly judicial resolution. The Company is currently evaluating the impact the SEC’s rule will have on its consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Revenues

Revenues	9 Months Ended
	Sep. 30, 2024
Revenue Recognition [Abstract]
Revenues	Revenues Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth ® , Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Consumables Point in time, as transfer of control occurs, generally upon shipment to, or receipt by, the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Advanced Services Over time, as services are provided Service A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $2.5 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively, and $6.9 million and $9.5 million for the nine months ended September 30, 2024 and 2023, respectively. Disaggregation of Revenues The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Connected devices, software licenses, and other $ 135,672 $ 167,560 $ 381,280 $ 500,182 Consumables 22,689 21,195 66,956 62,724 Technical services 59,583 57,303 177,419 167,851 Advanced Services 64,476 52,605 179,704 157,508 Total revenues $ 282,420 $ 298,663 $ 805,359 $ 888,265 The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) United States $ 258,177 $ 272,649 $ 731,670 $ 785,794 Rest of world (1) 24,243 26,014 73,689 102,471 Total revenues $ 282,420 $ 298,663 $ 805,359 $ 888,265 _________________________________________________ (1) No individual country represented more than 10% of total revenues. Contract Assets and Contract Liabilities The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 33,722 $ 22,524 Long-term unbilled receivables, net (2) 9,171 11,850 Total contract assets $ 42,893 $ 34,374 Short-term deferred revenues $ 152,367 $ 121,734 Long-term deferred revenues 69,811 58,622 Total contract liabilities $ 222,178 $ 180,356 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues. Short-term deferred revenues of $121.7 million as of December 31, 2023 include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million. During the three and nine months ended September 30, 2024, the Company recognized revenues of $21.6 million and $106.6 million, respectively, that were included in the corresponding gross short-term deferred revenues balance of $134.1 million as of December 31, 2023. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided. Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term technical and Advanced Services contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years. The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time. Advanced Services agreements are generally invoiced periodically on a monthly, quarterly or annual basis over the life of the agreement. In certain circumstances, portions of these agreements may be invoiced as a lump sum. In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues were $403.0 million as of September 30, 2024. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations. Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2024 and 2023. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable and unbilled receivables balances as of September 30, 2024 and December 31, 2023.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share The basic and diluted net income (loss) per share calculations for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands, except per share data) Net income (loss) $ 8,630 $ 5,553 $ (3,311) $ (5,996) Weighted-average shares outstanding – basic 46,153 45,333 45,947 45,117 Effect of dilutive securities from stock award plans 274 262 — — Weighted-average shares outstanding – diluted 46,427 45,595 45,947 45,117 Net income (loss) per share – basic $ 0.19 $ 0.12 $ (0.07) $ (0.13) Net income (loss) per share – diluted $ 0.19 $ 0.12 $ (0.07) $ (0.13) Anti-dilutive weighted-average shares related to stock award plans 2,687 2,727 3,767 3,536 Anti-dilutive weighted-average shares related to convertible senior notes and warrants 11,816 11,816 11,816 11,816

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $570.6 million and $468.0 million as of September 30, 2024 and December 31, 2023, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. As of September 30, 2024 and December 31, 2023, cash equivalents were $535.2 million and $451.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts. Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of September 30, 2024 and December 31, 2023, the fair value of the convertible senior notes was $548.8 million and $527.2 million, respectively, compared to their carrying values of $572.0 million and $569.7 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes,

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of September 30, 2024 and December 31, 2023 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 37,638 $ 51,439 Work in process 2,531 1,327 Finished goods 54,890 57,333 Total inventories $ 95,059 $ 110,099 Other current assets: Funds held for customers, including restricted cash (1) $ 31,849 $ 43,649 Net investment in sales-type leases, current portion 11,699 11,867 Prepaid income taxes 2,233 8,279 Other current assets (2) 19,146 7,714 Total other current assets $ 64,927 $ 71,509 Other long-term assets: External-use software development costs, net $ 59,557 $ 66,659 Unbilled receivables, net 9,171 11,850 Deferred debt issuance costs 3,134 3,718 Other long-term assets 9,872 8,239 Total other long-term assets $ 81,734 $ 90,466 Accrued liabilities: Operating lease liabilities, current portion $ 10,615 $ 10,518 Customer fund liabilities 31,849 43,649 Advance payments from customers 8,941 10,551 Rebate liabilities 58,079 51,277 Group purchasing organization fees 4,859 4,445 Taxes payable 2,842 2,191 Other accrued liabilities 27,068 26,645 Total accrued liabilities $ 144,253 $ 149,276 _________________________________________________ (1) Includes restricted cash of $22.3 million and $33.0 million as of September 30, 2024 and December 31, 2023, respectively. (2) Includes deferred cost of sales of $13.7 million as of September 30, 2024. The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Beginning balance $ (14,878) $ (14,176) $ (13,432) $ (17,087) Other comprehensive income (loss) 4,575 (2,953) 3,129 (42) Ending balance $ (10,303) $ (17,129) $ (10,303) $ (17,129)

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment The following table represents the property and equipment balances as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Equipment $ 99,491 $ 95,996 Furniture and fixtures 5,312 4,500 Leasehold improvements 17,996 17,919 Purchased software and internal-use software development costs 141,082 118,004 Construction in progress 9,119 11,614 Property and equipment, gross 273,000 248,033 Accumulated depreciation and amortization (161,256) (139,432) Total property and equipment, net $ 111,744 $ 108,601 Depreciation and amortization expense of property and equipment was $8.6 million and $6.7 million for the three months ended September 30, 2024 and 2023, respectively, and $25.9 million and $19.6 million for the nine months ended September 30, 2024 and 2023, respectively. The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) United States $ 107,551 $ 104,312 Rest of world 4,193 4,289 Total property and equipment, net $ 111,744 $ 108,601

External-Use Software Developme

External-Use Software Development Costs	9 Months Ended
	Sep. 30, 2024
Research and Development [Abstract]
External-Use Software Development Costs	External-Use Software Development Costs The carrying amounts of external-use software development costs as of September 30, 2024 and December 31, 2023 were as follows: September 30, December 31, (In thousands) Gross carrying amount $ 245,155 $ 239,038 Accumulated amortization (185,598) (172,379) External-use software development costs, net (1) $ 59,557 $ 66,659 _________________________________________________ (1) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The Company recorded $6.0 million and $7.1 million to cost of revenues for amortization of external-use software development costs for the three months ended September 30, 2024 and 2023, respectively, and $19.1 million and $21.9 million for the nine months ended September 30, 2024 and 2023, respectively. The estimated future amortization expenses for external-use software development costs were as follows: September 30, (In thousands) Remaining three months of 2024 $ 5,862 2025 20,545 2026 15,269 2027 9,336 2028 5,478 Thereafter 3,067 Total $ 59,557

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: (In thousands) Balance as of December 31, 2023 $ 735,810 Foreign currency exchange rate fluctuations 1,359 Balance as of September 30, 2024 $ 737,169 Intangible Assets, Net The carrying amounts and useful lives of intangible assets as of September 30, 2024 and December 31, 2023 were as follows: September 30, 2024 Gross carrying amount (1) Accumulated Foreign currency exchange Net carrying Useful life (In thousands, except for years) Customer relationships $ 307,418 $ (128,750) $ (1,197) $ 177,471 4 - 30 Acquired technology 46,134 (31,405) — 14,729 4 - 20 Trade names 2,400 (1,460) — 940 5 Patents 2,291 (1,462) — 829 2 - 20 Total intangible assets, net $ 358,243 $ (163,077) $ (1,197) $ 193,969 December 31, 2023 Gross carrying amount (1) Accumulated Foreign currency exchange Net carrying Useful life (In thousands, except for years) Customer relationships $ 307,418 $ (115,232) $ (1,326) $ 190,860 4 - 30 Acquired technology 84,876 (67,033) — 17,843 4 - 20 Backlog 1,800 (1,800) — — 2 Trade names 9,200 (7,680) — 1,520 5 - 12 Patents 2,404 (1,454) — 950 2 - 20 Total intangible assets, net $ 405,698 $ (193,199) $ (1,326) $ 211,173 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets. Amortization expense of intangible assets was $5.6 million and $7.7 million for the three months ended September 30, 2024 and 2023, respectively, and $17.3 million and $24.1 million for the nine months ended September 30, 2024 and 2023, respectively. The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2024 $ 5,526 2025 21,002 2026 18,087 2027 16,269 2028 15,184 Thereafter 117,901 Total $ 193,969

Debt and Credit Agreement

Debt and Credit Agreement	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt and Credit Agreement	Debt and Credit Agreement On November 15, 2019, Omnicell, Inc. entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. As referred to herein, “Omnicell, Inc.” refers only to Omnicell, Inc., excluding its subsidiaries. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement was subsequently amended on September 22, 2020 and March 29, 2023, to permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions (as described in Note 10, Convertible Senior Notes , of the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q), expand the Company’s flexibility to make restricted payments (including common stock repurchases), and replace the total net leverage covenant, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics. Omnicell, Inc. entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million and 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Current Revolving Credit Facility bear interest, at Omnicell, Inc.’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility Omnicell, Inc. is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement. The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. Omnicell, Inc.’s obligations under the Second A&R Credit Agreement and, at the election of Omnicell, Inc. and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, Omnicell, Inc. and certain of Omnicell, Inc.’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The refinancing of the Prior Credit Agreement on October 10, 2023 was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments. In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&R Credit Agreement. The Company incurred and capitalized an additional $3.0 million of debt issuance costs which are being amortized to interest expense using the straight-line method through 2028. As of both September 30, 2024 and December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility. As of September 30, 2024 and December 31, 2023, the Company had no outstanding balance under the Current Revolving Credit Facility. The Company was in compliance with all covenants as of September 30, 2024. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended September 30, 2024 and December 31, 2023, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2024, commencing on October 1, 2024, and were not convertible during the first quarter of 2024, commencing on January 1, 2024. As such, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of December 31, 2023. As the Notes will mature on September 15, 2025, the Company classified the Notes as a current liability as of September 30, 2024. Whether the Notes will be convertible following the fourth fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2024, none of the criteria for a fundamental change or a conversion rate adjustment had been met. As of September 30, 2024, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of September 30, 2024, the remaining life of the Notes and the related issuance cost accretion is approximately 1.0 year. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2024, the if-converted value of the Notes did not exceed the principal amount. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Principal amount $ 575,000 $ 575,000 Unamortized debt issuance costs (3,003) (5,338) Convertible senior notes, net $ 571,997 $ 569,662 The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of debt issuance costs $ 780 $ 773 $ 2,335 $ 2,316 Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, in September 2020, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Convertible Senior Notes	Debt and Credit Agreement On November 15, 2019, Omnicell, Inc. entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. As referred to herein, “Omnicell, Inc.” refers only to Omnicell, Inc., excluding its subsidiaries. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement was subsequently amended on September 22, 2020 and March 29, 2023, to permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions (as described in Note 10, Convertible Senior Notes , of the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q), expand the Company’s flexibility to make restricted payments (including common stock repurchases), and replace the total net leverage covenant, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics. Omnicell, Inc. entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million and 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Current Revolving Credit Facility bear interest, at Omnicell, Inc.’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility Omnicell, Inc. is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement. The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. Omnicell, Inc.’s obligations under the Second A&R Credit Agreement and, at the election of Omnicell, Inc. and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, Omnicell, Inc. and certain of Omnicell, Inc.’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The refinancing of the Prior Credit Agreement on October 10, 2023 was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments. In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the Second A&R Credit Agreement. The Company incurred and capitalized an additional $3.0 million of debt issuance costs which are being amortized to interest expense using the straight-line method through 2028. As of both September 30, 2024 and December 31, 2023, the Company had $350.0 million of funds available under the Current Revolving Credit Facility. As of September 30, 2024 and December 31, 2023, the Company had no outstanding balance under the Current Revolving Credit Facility. The Company was in compliance with all covenants as of September 30, 2024. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended September 30, 2024 and December 31, 2023, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2024, commencing on October 1, 2024, and were not convertible during the first quarter of 2024, commencing on January 1, 2024. As such, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of December 31, 2023. As the Notes will mature on September 15, 2025, the Company classified the Notes as a current liability as of September 30, 2024. Whether the Notes will be convertible following the fourth fiscal quarter of 2024 will depend on the satisfaction of the conversion conditions in the future. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2024, none of the criteria for a fundamental change or a conversion rate adjustment had been met. As of September 30, 2024, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of September 30, 2024, the remaining life of the Notes and the related issuance cost accretion is approximately 1.0 year. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2024, the if-converted value of the Notes did not exceed the principal amount. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Principal amount $ 575,000 $ 575,000 Unamortized debt issuance costs (3,003) (5,338) Convertible senior notes, net $ 571,997 $ 569,662 The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of debt issuance costs $ 780 $ 773 $ 2,335 $ 2,316 Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, in September 2020, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Lessor Leases

Lessor Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Lessor Leases	Lessor Leases Sales-Type Leases The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one ompounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Sales-type lease revenues $ 6,952 $ 14,388 $ 25,564 $ 27,960 Cost of sales-type lease revenues (3,912) (7,141) (15,209) (14,183) Selling profit on sales-type lease revenues $ 3,040 $ 7,247 $ 10,355 $ 13,777 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 74,595 $ 65,017 Less: Unearned interest income portion (12,321) (10,196) Net investment in sales-type leases 62,274 54,821 Less: Current portion (1) (11,699) (11,867) Long-term investment in sales-type leases, net $ 50,575 $ 42,954 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2024 $ 3,795 2025 14,238 2026 12,627 2027 11,080 2028 10,094 Thereafter 22,761 Total future minimum sales-type lease payments 74,595 Present value adjustment (12,321) Total net investment in sales-type leases $ 62,274 Operating Leases The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Rental income $ 1,230 $ 1,330 $ 2,797 $ 5,459
Lessor Leases	Lessor Leases Sales-Type Leases The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one ompounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Sales-type lease revenues $ 6,952 $ 14,388 $ 25,564 $ 27,960 Cost of sales-type lease revenues (3,912) (7,141) (15,209) (14,183) Selling profit on sales-type lease revenues $ 3,040 $ 7,247 $ 10,355 $ 13,777 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 74,595 $ 65,017 Less: Unearned interest income portion (12,321) (10,196) Net investment in sales-type leases 62,274 54,821 Less: Current portion (1) (11,699) (11,867) Long-term investment in sales-type leases, net $ 50,575 $ 42,954 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2024 $ 3,795 2025 14,238 2026 12,627 2027 11,080 2028 10,094 Thereafter 22,761 Total future minimum sales-type lease payments 74,595 Present value adjustment (12,321) Total net investment in sales-type leases $ 62,274 Operating Leases The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Rental income $ 1,230 $ 1,330 $ 2,797 $ 5,459

Lessee Leases

Lessee Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Lessee Leases	Lessee Leases The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2024 $ 3,296 2025 12,432 2026 11,561 2027 9,557 2028 8,193 Thereafter 2,271 Total operating lease payments 47,310 Present value adjustment (5,171) Total operating lease liabilities (1) $ 42,139 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.6 million and $31.5 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities Operating lease costs were $2.5 million and $2.6 million for the three months ended September 30, 2024 and 2023, respectively, and $7.7 million and $8.2 million for the nine months ended September 30, 2024 and 2023, respectively. Short-term lease costs and variable lease costs were not material for the three and nine months ended September 30, 2024 and 2023. The Company recorded impairment and abandonment charges to operating lease right-of-use assets of $7.8 million during the nine months ended September 30, 2023, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Condensed Consolidated Statements of Operations. Refer to Note 16, Restructuring Expenses, for additional information regarding the Company’s restructuring activities. The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 9,891 $ 10,100 Right-of-use assets obtained in exchange for new lease liabilities $ 5,831 $ 1,758 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2024 and December 31, 2023: September 30, December 31, Weighted-average remaining lease term, years 4.0 4.6 Weighted-average discount rate, % 5.8 % 5.8 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of September 30, 2024, the Company had non-cancelable purchase commitments of $111.2 million, of which $71.4 million are expected to be paid within the year ending December 31, 2024. Legal Proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome. The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. For the nine months ended September 30, 2024 and September 30, 2023, the Company recorded a provision for income taxes of $5.3 million and $4.4 million, respectively, by applying its estimated annual effective tax rate to its year-to-date measure of ordinary income and adjusted for $4.9 million and $5.6 million, respectively, of discrete income tax expense primarily from equity compensation. The effective tax rate for the nine months ended September 30, 2024 and 2023, differed from the statutory rate of 21% primarily due to the benefit of the research and development credits and a foreign-derived intangible income (“FDII”) benefit deduction, partially offset by the unfavorable impact of the non-deductible compensation and equity charges. The Organization for Economic Co-Operation and Development (“OECD”) introduced Base Erosion and Profit Shifting (“BEPS”) Pillar Two rules that impose a global minimum tax rate of 15% on multi-national corporations. The rules are effective for the Company’s financial year beginning January 1, 2024. These rules did not have an impact on the Company’s provision for income taxes for the nine months ended September 30, 2024. As of September 30, 2024 and December 31, 2023, the Company had gross unrecognized tax benefits of $11.5 million and $10.7 million, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. Accrued interest and penalties are included within other long-term liabilities on the Condensed Consolidated Balance Sheets. As of September 30, 2024 and December 31, 2023, the amount of accrued interest and penalties was $0.8 million and $0.4 million, respectively. The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, and the United Kingdom. With few exceptions, as of September 30, 2024, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2020, 2019, and 2019, respectively. Although the Company believes it has adequately provided for unrecognized tax benefits, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Cost of product and service revenues $ 1,709 $ 2,213 $ 4,884 $ 6,489 Research and development 1,062 1,917 3,276 5,220 Selling, general, and administrative 8,834 10,852 22,117 31,404 Total share-based compensation expense $ 11,605 $ 14,982 $ 30,277 $ 43,113 The Company capitalized approximately $1.0 million and $1.1 million during the three months ended September 30, 2024 and 2023, respectively, and $2.7 million and $3.3 million during the nine months ended September 30, 2024 and 2023, respectively, of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material share-based compensation expense to inventory during the three and nine months ended September 30, 2024 and 2023. Employee Stock Purchase Plan (“ESPP”) The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 33.7% - 58.7% 32.0% - 63.9% 33.7% - 58.7% 31.7% - 63.9% Risk-free interest rate, % 3.2% - 5.3% 0.2% - 5.5% 1.5% - 5.5% 0.1% - 5.5% Dividend yield, % — % — % — % — % For the nine months ended September 30, 2024 and 2023, employees purchased approximately 524,000 and 353,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $24.14 and $46.68, respectively. As of September 30, 2024, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $0.6 million and is expected to be recognized over a weighted-average period of 1.6 years. Stock Options The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended (the “2009 Plan”) for the nine months ended September 30, 2023. There were no stock options granted during the three and nine months ended September 30, 2024 or the three months ended September 30, 2023. Nine Months Ended September 30, 2023 Expected life, years 3.2 Expected volatility, % 44.8 % Risk-free interest rate, % 3.7 % Estimated forfeiture rate, % 10.0 % Dividend yield, % — % The following table summarizes the stock option activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2023 2,023 $ 67.68 4.6 $ 1,013 Granted — — Exercised (16) 30.54 Expired (209) 73.50 Forfeited (23) 63.93 Outstanding at September 30, 2024 1,775 $ 67.38 4.1 $ 2,399 Exercisable at September 30, 2024 1,762 $ 66.97 4.0 $ 2,399 Vested and expected to vest at September 30, 2024 and thereafter 1,774 $ 67.36 4.1 $ 2,399 As of September 30, 2024, total unrecognized compensation cost related to unvested stock options was $0.3 million, which is expected to be recognized over a weighted-average vesting period of 0.4 years. Restricted Stock Units (“RSUs”) The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2023 1,078 $ 84.66 1.5 $ 40,551 Granted (Awarded) 1,023 40.04 Vested (Released) (297) 88.81 Forfeited (130) 78.53 Outstanding and unvested at September 30, 2024 1,674 $ 57.13 1.7 $ 72,966 As of September 30, 2024, total unrecognized compensation cost related to RSUs was $62.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.2 years. Restricted Stock Awards (“RSAs”) The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2023 24 $ 70.96 Granted (Awarded) 51 31.94 Vested (Released) (26) 67.32 Outstanding and unvested at September 30, 2024 49 $ 31.91 As of September 30, 2024, total unrecognized compensation cost related to RSAs was $0.8 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.6 years. Performance-Based Stock Unit Awards (“PSUs”) The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2023 75 $ 127.14 Granted (Awarded) 177 28.67 Vested (Released) (5) 157.56 Forfeited (65) 122.29 Outstanding and unvested at September 30, 2024 182 $ 32.33 As of September 30, 2024, total unrecognized compensation cost related to PSUs was approximately $3.9 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.6 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2024: Number of Shares (In thousands) Stock options outstanding 1,775 Non-vested restricted stock awards 1,905 Shares authorized for future issuance 3,396 ESPP shares available for future issuance 2,726 Total shares reserved for future issuance 9,802 Stock Repurchase Programs On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program, which does not expire, providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). As of September 30, 2024, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The timing, price, and volume of repurchases are to be based on market conditions, relevant securities laws, and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions, or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of the Second A&R Credit Agreement, as amended. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time. During the three and nine months ended September 30, 2024 and 2023, the Company did not repurchase any of its outstanding common stock under the 2016 Repurchase Program.

Restructuring Expenses

Restructuring Expenses	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (the “2022 Plan”), as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds. During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the three months ended September 30, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the 2022 Plan. During the nine months ended September 30, 2023, the Company incurred $5.5 million of employee severance costs and related expenses, net of reversals, in connection with the 2022 Plan. As of September 30, 2024, there was no unpaid balance related to the 2022 Plan. On November 2, 2023, the Company committed to a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. The Company did not incur any material expenses related to the 2023 Plan during both the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, the unpaid balance related to the 2023 Plan was $0.8 million and $8.9 million, respectively. On April 26, 2024, the Company’s management committed to the wind down of the Company’s Medimat Robotic Dispensing System (“RDS”) product line, subject to local law and statutory works council consultation requirements. During the three and nine months ended September 30, 2024, the Company incurred approximately $0.6 million and $4.1 million, respectively, of employee severance costs and other expenses related to the RDS product line wind down, net of immaterial reversals of previously recognized restructuring expenses, the majority of which were unpaid as of September 30, 2024. In addition, during the nine months ended September 30, 2024, the Company incurred $5.4 million of inventory write-down charges related to the RDS product line wind down that were recorded to cost of revenues in the Company’s Condensed Consolidated Statements of Operations. Refer to Note 12, Lessee Leases , for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities. The following table summarizes the total employee-related restructuring expense, net of reversals, recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Cost of product and service revenues $ 642 $ (280) $ 3,338 $ 102 Research and development (15) (25) 296 467 Selling, general, and administrative (7) (276) 149 4,885 Total restructuring expense $ 620 $ (581) $ 3,783 $ 5,454

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ 8,630	$ 3,735	$ (15,676)	$ 5,553	$ 3,451	$ (15,000)	$ (3,311)	$ (5,996)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2024 and December 31, 2023, the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 28, 2024. The Company’s results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024, or for any future period.
Principles of Consolidation	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2024, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.
Segment Reporting	The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.
Recently Adopted and Issued Authoritative Guidance	There was no recently adopted authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date. Recently Issued Authoritative Guidance In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which requires public entities to disclose significant segment expenses that are regularly provided to the CODM. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. The amendments are effective for the Company’s annual periods beginning January 1, 2024, and for interim periods within fiscal years beginning January 1, 2025. Retrospective application is required, with early adoption permitted. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its balance sheets, statements of operations, or statements of cash flows, as the anticipated changes will be the inclusion of additional disclosures related to the Company’s single reportable segment. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements. In March 2024, the SEC issued final rules under SEC Release No. 33-11275, “The Enhancement and Standardization of Climate-Related Disclosures for Investors,” to require registrants to disclose certain climate-related information, including Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics, if material, in registration statements and annual reports. In April 2024, the SEC voluntarily stayed its climate disclosure rules as a result of pending legal challenges to facilitate an orderly judicial resolution. The Company is currently evaluating the impact the SEC’s rule will have on its consolidated financial statements.
Revenue Recognition	The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth ® , Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Consumables Point in time, as transfer of control occurs, generally upon shipment to, or receipt by, the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Advanced Services Over time, as services are provided Service
Fair Value Hierarchy	The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue Recognition [Abstract]
Schedule of Revenue Recognition for Revenue Categories	The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Consumables Point in time, as transfer of control occurs, generally upon shipment to, or receipt by, the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Advanced Services Over time, as services are provided Service
Schedule of Disaggregation of Revenues by Revenue Type	The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Connected devices, software licenses, and other $ 135,672 $ 167,560 $ 381,280 $ 500,182 Consumables 22,689 21,195 66,956 62,724 Technical services 59,583 57,303 177,419 167,851 Advanced Services 64,476 52,605 179,704 157,508 Total revenues $ 282,420 $ 298,663 $ 805,359 $ 888,265
Schedule of Disaggregation of Revenues by Geographical Location	The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) United States $ 258,177 $ 272,649 $ 731,670 $ 785,794 Rest of world (1) 24,243 26,014 73,689 102,471 Total revenues $ 282,420 $ 298,663 $ 805,359 $ 888,265 _________________________________________________ (1) No individual country represented more than 10% of total revenues.
Schedule of Contract Asset and Liabilities	The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 33,722 $ 22,524 Long-term unbilled receivables, net (2) 9,171 11,850 Total contract assets $ 42,893 $ 34,374 Short-term deferred revenues $ 152,367 $ 121,734 Long-term deferred revenues 69,811 58,622 Total contract liabilities $ 222,178 $ 180,356 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2)

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income (Loss) Per Share	The basic and diluted net income (loss) per share calculations for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands, except per share data) Net income (loss) $ 8,630 $ 5,553 $ (3,311) $ (5,996) Weighted-average shares outstanding – basic 46,153 45,333 45,947 45,117 Effect of dilutive securities from stock award plans 274 262 — — Weighted-average shares outstanding – diluted 46,427 45,595 45,947 45,117 Net income (loss) per share – basic $ 0.19 $ 0.12 $ (0.07) $ (0.13) Net income (loss) per share – diluted $ 0.19 $ 0.12 $ (0.07) $ (0.13) Anti-dilutive weighted-average shares related to stock award plans 2,687 2,727 3,767 3,536 Anti-dilutive weighted-average shares related to convertible senior notes and warrants 11,816 11,816 11,816 11,816

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Balance Sheet Components	Balance sheet details as of September 30, 2024 and December 31, 2023 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 37,638 $ 51,439 Work in process 2,531 1,327 Finished goods 54,890 57,333 Total inventories $ 95,059 $ 110,099 Other current assets: Funds held for customers, including restricted cash (1) $ 31,849 $ 43,649 Net investment in sales-type leases, current portion 11,699 11,867 Prepaid income taxes 2,233 8,279 Other current assets (2) 19,146 7,714 Total other current assets $ 64,927 $ 71,509 Other long-term assets: External-use software development costs, net $ 59,557 $ 66,659 Unbilled receivables, net 9,171 11,850 Deferred debt issuance costs 3,134 3,718 Other long-term assets 9,872 8,239 Total other long-term assets $ 81,734 $ 90,466 Accrued liabilities: Operating lease liabilities, current portion $ 10,615 $ 10,518 Customer fund liabilities 31,849 43,649 Advance payments from customers 8,941 10,551 Rebate liabilities 58,079 51,277 Group purchasing organization fees 4,859 4,445 Taxes payable 2,842 2,191 Other accrued liabilities 27,068 26,645 Total accrued liabilities $ 144,253 $ 149,276 _________________________________________________ (1) Includes restricted cash of $22.3 million and $33.0 million as of September 30, 2024 and December 31, 2023, respectively. (2) Includes deferred cost of sales of $13.7 million as of September 30, 2024.
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Beginning balance $ (14,878) $ (14,176) $ (13,432) $ (17,087) Other comprehensive income (loss) 4,575 (2,953) 3,129 (42) Ending balance $ (10,303) $ (17,129) $ (10,303) $ (17,129)

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment Balances	The following table represents the property and equipment balances as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Equipment $ 99,491 $ 95,996 Furniture and fixtures 5,312 4,500 Leasehold improvements 17,996 17,919 Purchased software and internal-use software development costs 141,082 118,004 Construction in progress 9,119 11,614 Property and equipment, gross 273,000 248,033 Accumulated depreciation and amortization (161,256) (139,432) Total property and equipment, net $ 111,744 $ 108,601
Schedule of Geographic Information for Property and Equipment, Net	The following table summarizes the geographic information for property and equipment, net, as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) United States $ 107,551 $ 104,312 Rest of world 4,193 4,289 Total property and equipment, net $ 111,744 $ 108,601

External-Use Software Develop_2

External-Use Software Development Costs (Tables)	9 Months Ended
	Sep. 30, 2024
Research and Development [Abstract]
Schedule of Capitalized Computer Software	The carrying amounts of external-use software development costs as of September 30, 2024 and December 31, 2023 were as follows: September 30, December 31, (In thousands) Gross carrying amount $ 245,155 $ 239,038 Accumulated amortization (185,598) (172,379) External-use software development costs, net (1) $ 59,557 $ 66,659 _________________________________________________ (1) Included in other long-term assets in the Condensed Consolidated Balance Sheets.
Schedule of Future Amortization Expenses For Capitalized Software Development Costs	The estimated future amortization expenses for external-use software development costs were as follows: September 30, (In thousands) Remaining three months of 2024 $ 5,862 2025 20,545 2026 15,269 2027 9,336 2028 5,478 Thereafter 3,067 Total $ 59,557

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: (In thousands) Balance as of December 31, 2023 $ 735,810 Foreign currency exchange rate fluctuations 1,359 Balance as of September 30, 2024 $ 737,169
Schedule of Carrying Amounts and Useful Lives of Intangible Assets	The carrying amounts and useful lives of intangible assets as of September 30, 2024 and December 31, 2023 were as follows: September 30, 2024 Gross carrying amount (1) Accumulated Foreign currency exchange Net carrying Useful life (In thousands, except for years) Customer relationships $ 307,418 $ (128,750) $ (1,197) $ 177,471 4 - 30 Acquired technology 46,134 (31,405) — 14,729 4 - 20 Trade names 2,400 (1,460) — 940 5 Patents 2,291 (1,462) — 829 2 - 20 Total intangible assets, net $ 358,243 $ (163,077) $ (1,197) $ 193,969 December 31, 2023 Gross carrying amount (1) Accumulated Foreign currency exchange Net carrying Useful life (In thousands, except for years) Customer relationships $ 307,418 $ (115,232) $ (1,326) $ 190,860 4 - 30 Acquired technology 84,876 (67,033) — 17,843 4 - 20 Backlog 1,800 (1,800) — — 2 Trade names 9,200 (7,680) — 1,520 5 - 12 Patents 2,404 (1,454) — 950 2 - 20 Total intangible assets, net $ 405,698 $ (193,199) $ (1,326) $ 211,173 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets.
Schedule of Estimated Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2024 $ 5,526 2025 21,002 2026 18,087 2027 16,269 2028 15,184 Thereafter 117,901 Total $ 193,969

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Convertible Debt Balances	The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Principal amount $ 575,000 $ 575,000 Unamortized debt issuance costs (3,003) (5,338) Convertible senior notes, net $ 571,997 $ 569,662
Schedule of Components of Interest Expense	The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of debt issuance costs $ 780 $ 773 $ 2,335 $ 2,316

Lessor Leases (Tables)

Lessor Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Income Recognized from Sales-Type Leases	The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Sales-type lease revenues $ 6,952 $ 14,388 $ 25,564 $ 27,960 Cost of sales-type lease revenues (3,912) (7,141) (15,209) (14,183) Selling profit on sales-type lease revenues $ 3,040 $ 7,247 $ 10,355 $ 13,777
Schedule of Components of Sales-Type Lease Receivables	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2024 and December 31, 2023: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 74,595 $ 65,017 Less: Unearned interest income portion (12,321) (10,196) Net investment in sales-type leases 62,274 54,821 Less: Current portion (1) (11,699) (11,867) Long-term investment in sales-type leases, net $ 50,575 $ 42,954 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Schedule of Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases	The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2024 $ 3,795 2025 14,238 2026 12,627 2027 11,080 2028 10,094 Thereafter 22,761 Total future minimum sales-type lease payments 74,595 Present value adjustment (12,321) Total net investment in sales-type leases $ 62,274
Schedule of Income Recognized from Operating Leases	The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Rental income $ 1,230 $ 1,330 $ 2,797 $ 5,459

Lessee Leases (Tables)

Lessee Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities	The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2024 $ 3,296 2025 12,432 2026 11,561 2027 9,557 2028 8,193 Thereafter 2,271 Total operating lease payments 47,310 Present value adjustment (5,171) Total operating lease liabilities (1) $ 42,139 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.6 million and $31.5 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities
Schedule of Supplemental Cash Flow Information and Weighted-Average Remaining Lease Term and Discount Rate	The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 9,891 $ 10,100 Right-of-use assets obtained in exchange for new lease liabilities $ 5,831 $ 1,758 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2024 and December 31, 2023: September 30, December 31, Weighted-average remaining lease term, years 4.0 4.6 Weighted-average discount rate, % 5.8 % 5.8 %

Employee Benefits and Share-B_2

Employee Benefits and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-Based Compensation Expense	The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Cost of product and service revenues $ 1,709 $ 2,213 $ 4,884 $ 6,489 Research and development 1,062 1,917 3,276 5,220 Selling, general, and administrative 8,834 10,852 22,117 31,404 Total share-based compensation expense $ 11,605 $ 14,982 $ 30,277 $ 43,113
Schedule of Assumptions Used to Value ESPP Shares	The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 33.7% - 58.7% 32.0% - 63.9% 33.7% - 58.7% 31.7% - 63.9% Risk-free interest rate, % 3.2% - 5.3% 0.2% - 5.5% 1.5% - 5.5% 0.1% - 5.5% Dividend yield, % — % — % — % — %
Schedule of Assumptions Used to Value Stock Options Granted	The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended (the “2009 Plan”) for the nine months ended September 30, 2023. There were no stock options granted during the three and nine months ended September 30, 2024 or the three months ended September 30, 2023. Nine Months Ended September 30, 2023 Expected life, years 3.2 Expected volatility, % 44.8 % Risk-free interest rate, % 3.7 % Estimated forfeiture rate, % 10.0 % Dividend yield, % — %
Schedule of Share Option Activity	The following table summarizes the stock option activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2023 2,023 $ 67.68 4.6 $ 1,013 Granted — — Exercised (16) 30.54 Expired (209) 73.50 Forfeited (23) 63.93 Outstanding at September 30, 2024 1,775 $ 67.38 4.1 $ 2,399 Exercisable at September 30, 2024 1,762 $ 66.97 4.0 $ 2,399 Vested and expected to vest at September 30, 2024 and thereafter 1,774 $ 67.36 4.1 $ 2,399
Schedule of Restricted Stock Unit Activity	The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2023 1,078 $ 84.66 1.5 $ 40,551 Granted (Awarded) 1,023 40.04 Vested (Released) (297) 88.81 Forfeited (130) 78.53 Outstanding and unvested at September 30, 2024 1,674 $ 57.13 1.7 $ 72,966
Schedule of Restricted Stock Awards Activity	The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2023 24 $ 70.96 Granted (Awarded) 51 31.94 Vested (Released) (26) 67.32 Outstanding and unvested at September 30, 2024 49 $ 31.91
Schedule of Performance-Based Restricted Stock Activity	The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2024: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2023 75 $ 127.14 Granted (Awarded) 177 28.67 Vested (Released) (5) 157.56 Forfeited (65) 122.29 Outstanding and unvested at September 30, 2024 182 $ 32.33
Schedule of Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2024: Number of Shares (In thousands) Stock options outstanding 1,775 Non-vested restricted stock awards 1,905 Shares authorized for future issuance 3,396 ESPP shares available for future issuance 2,726 Total shares reserved for future issuance 9,802

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations	The following table summarizes the total employee-related restructuring expense, net of reversals, recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (In thousands) Cost of product and service revenues $ 642 $ (280) $ 3,338 $ 102 Research and development (15) (25) 296 467 Selling, general, and administrative (7) (276) 149 4,885 Total restructuring expense $ 620 $ (581) $ 3,783 $ 5,454

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2024 segment
Accounting Policies [Abstract]
Number of operating segments	1
Number of reportable segments	1

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Fees to GPOs	$ 2,500	$ 3,600	$ 6,900	$ 9,500
Short-term deferred revenues	152,367		152,367		$ 121,734
Deferred cost of sales	13,700		13,700		12,400
Deferred revenues recognized	$ 21,600		$ 106,600
Short-term deferred revenues, gross					$ 134,100
Deferred revenue, period	10 years		10 years
Remaining performance obligation	$ 403,000		$ 403,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	10 years		10 years

Revenues - Schedule of Disaggre

Revenues - Schedule of Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]
Total revenues	$ 282,420	$ 298,663	$ 805,359	$ 888,265
Connected devices, software licenses, and other
Revenue from External Customer [Line Items]
Total revenues	135,672	167,560	381,280	500,182
Consumables
Revenue from External Customer [Line Items]
Total revenues	22,689	21,195	66,956	62,724
Technical services
Revenue from External Customer [Line Items]
Total revenues	59,583	57,303	177,419	167,851
Advanced Services
Revenue from External Customer [Line Items]
Total revenues	$ 64,476	$ 52,605	$ 179,704	$ 157,508

Revenues - Schedule of Disagg_2

Revenues - Schedule of Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]
Total revenues	$ 282,420	$ 298,663	$ 805,359	$ 888,265
United States
Revenue from External Customer [Line Items]
Total revenues	258,177	272,649	731,670	785,794
Rest of world
Revenue from External Customer [Line Items]
Total revenues	$ 24,243	$ 26,014	$ 73,689	$ 102,471

Revenues - Schedule of Contract

Revenues - Schedule of Contract Asset and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Revenue Recognition [Abstract]
Short-term unbilled receivables, net	$ 33,722	$ 22,524
Long-term unbilled receivables, net	9,171	11,850
Total contract assets	42,893	34,374
Short-term deferred revenues	152,367	121,734
Long-term deferred revenues	69,811	58,622
Total contract liabilities	$ 222,178	$ 180,356

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	$ 8,630	$ 3,735	$ (15,676)	$ 5,553	$ 3,451	$ (15,000)	$ (3,311)	$ (5,996)
Weighted-average shares outstanding – basic (in shares)	46,153			45,333			45,947	45,117
Effect of dilutive securities from stock award plans (in shares)	274			262			0	0
Weighted-average shares outstanding – diluted (in shares)	46,427			45,595			45,947	45,117
Net income (loss) per share – basic (in dollars per share)	$ 0.19			$ 0.12			$ (0.07)	$ (0.13)
Net income (loss) per share – diluted (in dollars per share)	$ 0.19			$ 0.12			$ (0.07)	$ (0.13)
Stock Award Plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted-average shares (in shares)	2,687			2,727			3,767	3,536
Convertible Senior Notes and Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted-average shares (in shares)	11,816			11,816			11,816	11,816

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 570,628	$ 467,972	$ 446,840
Cash equivalents	535,200	451,000
Convertible Senior Notes | Convertible Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	548,800	527,200
Long-term debt	$ 571,997	$ 569,662

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventories:
Raw materials	$ 37,638	$ 51,439
Work in process	2,531	1,327
Finished goods	54,890	57,333
Total inventories	95,059	110,099
Other current assets:
Funds held for customers, including restricted cash	$ 31,849	$ 43,649
Restricted Cash, Statement of Financial Position [Extensible Enumeration]	Total other current assets	Total other current assets
Net investment in sales-type leases, current portion	$ 11,699	$ 11,867
Prepaid income taxes	2,233	8,279
Other current assets	19,146	7,714
Total other current assets	64,927	71,509
Other long-term assets:
External-use software development costs, net	59,557	66,659
Unbilled receivables, net	9,171	11,850
Deferred debt issuance costs	3,134	3,718
Other long-term assets	9,872	8,239
Total other long-term assets	81,734	90,466
Accrued liabilities:
Operating lease liabilities, current portion	$ 10,615	$ 10,518
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total accrued liabilities	Total accrued liabilities
Customer fund liabilities	$ 31,849	$ 43,649
Advance payments from customers	8,941	10,551
Rebate liabilities	58,079	51,277
Group purchasing organization fees	4,859	4,445
Taxes payable	2,842	2,191
Other accrued liabilities	27,068	26,645
Total accrued liabilities	144,253	149,276
Restricted cash	22,300	33,000
Deferred cost of sales	$ 13,700	$ 12,400

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 1,202,808	$ 1,188,597	$ 1,188,954	$ 1,163,565	$ 1,142,541	$ 1,130,137	$ 1,188,954	$ 1,130,137
Other comprehensive income (loss)	4,575	(47)	(1,399)	(2,953)	1,432	1,479	3,129	(42)
Ending balance	1,231,328	1,202,808	1,188,597	1,187,436	1,163,565	1,142,541	1,231,328	1,187,436
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(14,878)	(14,831)	(13,432)	(14,176)	(15,608)	(17,087)	(13,432)	(17,087)
Other comprehensive income (loss)	4,575	(47)	(1,399)	(2,953)	1,432	1,479
Ending balance	$ (10,303)	$ (14,878)	$ (14,831)	$ (17,129)	$ (14,176)	$ (15,608)	$ (10,303)	$ (17,129)

Property and Equipment - Proper

Property and Equipment - Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 273,000	$ 248,033
Accumulated depreciation and amortization	(161,256)	(139,432)
Total property and equipment, net	111,744	108,601
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	99,491	95,996
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,312	4,500
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,996	17,919
Purchased software and internal-use software development costs
Property, Plant and Equipment [Line Items]
Property and equipment, gross	141,082	118,004
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 9,119	$ 11,614

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 8.6	$ 6.7	$ 25.9	$ 19.6

Property and Equipment - Geogra

Property and Equipment - Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment, net	$ 111,744	$ 108,601
United States
Property, Plant and Equipment [Line Items]
Total property and equipment, net	107,551	104,312
Rest of world
Property, Plant and Equipment [Line Items]
Total property and equipment, net	$ 4,193	$ 4,289

External-Use Software Develop_3

External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Research and Development [Abstract]
Gross carrying amount	$ 245,155	$ 239,038
Accumulated amortization	(185,598)	(172,379)
Total	$ 59,557	$ 66,659

External-Use Software Develop_4

External-Use Software Development Costs - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Research and Development [Abstract]
Amortization of capitalized software development costs	$ 6	$ 7.1	$ 19.1	$ 21.9

External-Use Software Develop_5

External-Use Software Development Costs - Future Amortization Expenses For Capitalized Software Development Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Research and Development [Abstract]
Remaining three months of 2024	$ 5,862
2025	20,545
2026	15,269
2027	9,336
2028	5,478
Thereafter	3,067
Total	$ 59,557	$ 66,659

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 735,810
Foreign currency exchange rate fluctuations	1,359
Balance at end of period	$ 737,169

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 358,243	$ 405,698
Accumulated amortization	(163,077)	(193,199)
Foreign currency exchange rate fluctuations	(1,197)	(1,326)
Net carrying amount	193,969	211,173
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	307,418	307,418
Accumulated amortization	(128,750)	(115,232)
Foreign currency exchange rate fluctuations	(1,197)	(1,326)
Net carrying amount	$ 177,471	$ 190,860
Customer relationships | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	4 years
Customer relationships | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 46,134	$ 84,876
Accumulated amortization	(31,405)	(67,033)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 14,729	$ 17,843
Acquired technology | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	4 years
Acquired technology | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 1,800
Accumulated amortization		(1,800)
Foreign currency exchange rate fluctuations		0
Net carrying amount		$ 0
Useful life		2 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,400	$ 9,200
Accumulated amortization	(1,460)	(7,680)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 940	$ 1,520
Useful life	5 years
Trade names | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life		5 years
Trade names | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life		12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,291	$ 2,404
Accumulated amortization	(1,462)	(1,454)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 829	$ 950
Patents | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	2 years	2 years
Patents | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 5.6	$ 7.7	$ 17.3	$ 24.1

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining three months of 2024	$ 5,526
2025	21,002
2026	18,087
2027	16,269
2028	15,184
Thereafter	117,901
Total	$ 193,969	$ 211,173

Debt and Credit Agreement (Deta

Debt and Credit Agreement (Details) - Line of Credit - USD ($)	Oct. 10, 2023	Nov. 15, 2019	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Debt issuance costs, gross	$ 3,000,000
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities
Debt Instrument [Line Items]
Maximum secured net leverage ratio	3
Minimum interest coverage ratio	3
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Federal Funds
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | One Month Adjusted Term Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Spread on variable interest rate	1%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.20%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Minimum | Applicable Margin
Debt Instrument [Line Items]
Spread on variable interest rate	1.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Minimum | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.35%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Maximum | Applicable Margin
Debt Instrument [Line Items]
Spread on variable interest rate	2.25%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Maximum | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin
Debt Instrument [Line Items]
Spread on variable interest rate	1.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit			$ 0	$ 0
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Term of debt instrument		5 years
Maximum borrowing capacity		$ 500,000,000
Remaining borrowing capacity			$ 350,000,000	$ 350,000,000
Revolving Credit Facility | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities
Debt Instrument [Line Items]
Term of debt instrument	5 years
Maximum borrowing capacity	$ 350,000,000
Accordion feature, higher borrowing capacity option	$ 250,000,000
EBITDA, prior year, percentage	100%
Incremental Loan Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		250,000,000
Letter of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		15,000,000
Letter of Credit | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 15,000,000
Swing Line Loan | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 25,000,000
Swing Line Loan | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000

Convertible Senior Notes - Narr

Convertible Senior Notes - Narrative (Details) $ / shares in Units, shares in Millions			9 Months Ended
	Dec. 13, 2021 USD ($) $ / shares	Sep. 25, 2020 USD ($) day $ / shares shares	Sep. 30, 2024 USD ($) day shares	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Cost of convertible note hedge		$ 100,600,000
Proceeds from sale of warrants		51,300,000
Convertible Note Hedge
Debt Instrument [Line Items]
Deferred tax asset related to the convertible note hedge transaction		$ 25,800,000
Convertible Note Hedge Rights
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) | shares		5.9
Strike price (in dollars per share) | $ / shares		$ 97.32
Warrants
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) | shares		5.9
Strike price (in dollars per share) | $ / shares		$ 141.56
Convertible Senior Notes
Debt Instrument [Line Items]
Debt instrument, convertible, principal amount of notes, minimum	$ 1,000
Debt instrument, convertible, maximum cash	1,000
Debt instrument, convertible, consideration in excess, amount	$ 1,000
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Interest rate		0.25%
Principal amount		$ 575,000,000	$ 575,000,000	$ 575,000,000
Additional principal amount subject to purchasers' option		75,000,000
Proceeds from issuance of convertible senior notes, net of issuance costs		559,700,000
Debt issuance costs incurred and capitalized		$ 15,300,000
Conversion ratio	0.0102751
Conversion price (in dollars per share) | $ / shares	$ 97.32
Repurchase price as a percent of principal amount		100%	100%
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes			$ 150,000,000
Effective interest rate			0.80%
Remaining life of debt discount and issuance cost accretion			1 year
Maximum number of shares issuable upon conversion (in shares) | shares			5.9
Convertible Senior Notes | Convertible Debt | Period 1
Debt Instrument [Line Items]
Threshold trading days | day		20	20
Threshold consecutive trading days | day		30	30
Threshold percentage of stock price trigger		130%	130%
Convertible Senior Notes | Convertible Debt | Period 2
Debt Instrument [Line Items]
Threshold trading days | day		5
Threshold consecutive trading days | day		10
Threshold percentage of stock price trigger		98%

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 25, 2020
Debt Instrument [Line Items]
Principal amount	$ 575,000,000	$ 575,000,000	$ 575,000,000
Unamortized debt issuance costs	(3,003,000)	(5,338,000)
Convertible senior notes, net	$ 571,997,000	$ 569,662,000

Convertible Senior Notes - Comp

Convertible Senior Notes - Components of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 2,917	$ 3,139
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Contractual coupon interest	$ 359	$ 359	1,078	1,078
Amortization of debt issuance costs	$ 780	$ 773	$ 2,335	$ 2,316

Lessor Leases - Narrative (Deta

Lessor Leases - Narrative (Details)	Sep. 30, 2024
Minimum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	1 year
Maximum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	10 years

Lessor Leases - Schedule of Inc

Lessor Leases - Schedule of Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Sales-type lease revenues	$ 6,952	$ 14,388	$ 25,564	$ 27,960
Cost of sales-type lease revenues	(3,912)	(7,141)	(15,209)	(14,183)
Selling profit on sales-type lease revenues	$ 3,040	$ 7,247	$ 10,355	$ 13,777

Lessor Leases - Schedule of Com

Lessor Leases - Schedule of Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Net minimum lease payments to be received	$ 74,595	$ 65,017
Less: Unearned interest income portion	(12,321)	(10,196)
Net investment in sales-type leases	62,274	54,821
Less: Current portion	(11,699)	(11,867)
Long-term investment in sales-type leases, net	$ 50,575	$ 42,954

Lessor Leases - Schedule of Mat

Lessor Leases - Schedule of Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Remaining three months of 2024	$ 3,795
2025	14,238
2026	12,627
2027	11,080
2028	10,094
Thereafter	22,761
Net minimum lease payments to be received	74,595	$ 65,017
Present value adjustment	(12,321)	$ (10,196)
Total net investment in sales-type leases	$ 62,274

Lessor Leases - Schedule of I_2

Lessor Leases - Schedule of Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Rental income	$ 1,230	$ 1,330	$ 2,797	$ 5,459

Lessee Leases - Narrative (Deta

Lessee Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 2,500	$ 2,600	$ 7,700	$ 8,200
Impairment and abandonment of operating lease right-of-use assets related to facilities			$ 0	$ 7,815
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases	12 years		12 years

Lessee Leases - Schedule of Mat

Lessee Leases - Schedule of Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Remaining three months of 2024	$ 3,296
2025	12,432
2026	11,561
2027	9,557
2028	8,193
Thereafter	2,271
Total operating lease payments	47,310
Present value adjustment	(5,171)
Total operating lease liabilities	42,139
Current portion of operating lease liabilities	10,615	$ 10,518
Long-term portion of operating lease liabilities	$ 31,524	$ 33,910
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities

Lessee Leases - Schedule of Sup

Lessee Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 9,891	$ 10,100
Right-of-use assets obtained in exchange for new lease liabilities	$ 5,831	$ 1,758

Lessee Leases - Schedule of Wei

Lessee Leases - Schedule of Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted-average remaining lease term, years	4 years	4 years 7 months 6 days
Weighted-average discount rate, %	5.80%	5.80%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable purchase commitments	$ 111.2
Non-cancelable purchase commitments expected to be paid within the year	$ 71.4

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 2,997	$ 1,829	$ 5,304	$ 4,405
Ordinary income effective rate rate amount			4,900	$ 5,600
Unrecognized tax benefits	11,500		11,500		$ 10,700
Accrued interest and penalties	$ 800		$ 800		$ 400

Employee Benefits and Share-B_3

Employee Benefits and Share-Based Compensation - Schedule of Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 11,605	$ 14,982	$ 30,277	$ 43,113
Cost of product and service revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	1,709	2,213	4,884	6,489
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	1,062	1,917	3,276	5,220
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 8,834	$ 10,852	$ 22,117	$ 31,404

Employee Benefits and Share-B_4

Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 02, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, amount capitalized	$ 1,000,000	$ 1,100,000	$ 2,700,000	$ 3,300,000
Shares purchased under ESPP (in shares)			524,000	353,000
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)					$ 50,000,000
Remaining value of shares authorized for repurchase under stock repurchase programs	$ 2,700,000		$ 2,700,000
Number of shares repurchased (in shares)	0	0	0	0
ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average price of shares purchased (in dollars per share)			$ 24.14	$ 46.68
Unrecognized compensation cost	$ 600,000		$ 600,000
Weighted average period of compensation cost not yet recognized			1 year 7 months 6 days
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost of unvested stock options	300,000		$ 300,000
2009 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized			4 months 24 days
2009 Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	62,500,000		$ 62,500,000
Weighted average period of compensation cost not yet recognized			3 years 2 months 12 days
2009 Plan | RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	800,000		$ 800,000
Weighted average period of compensation cost not yet recognized			7 months 6 days
2009 Plan | PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 3,900,000		$ 3,900,000
Weighted average period of compensation cost not yet recognized			1 year 7 months 6 days

Employee Benefits and Share-B_5

Employee Benefits and Share-Based Compensation - Schedule of Assumptions Used to Value ESPP Shares (Details) - ESPP shares available for future issuance	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (minimum)	33.70%	32%	33.70%	31.70%
Expected volatility (maximum)	58.70%	63.90%	58.70%	63.90%
Risk-free interest rate (minimum)	3.20%	0.20%	1.50%	0.10%
Risk-free interest rate (maximum)	5.30%	5.50%	5.50%	5.50%
Dividend yield	0%	0%	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years	2 years

Employee Benefits and Share-B_6

Employee Benefits and Share-Based Compensation - Schedule of Assumptions Used to Value Stock Options Granted (Details) - Stock Options	9 Months Ended
	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	3 years 2 months 12 days
Expected volatility	44.80%
Risk-free interest rate	3.70%
Estimated forfeiture rate	10%
Dividend yield	0%

Employee Benefits and Share-B_7

Employee Benefits and Share-Based Compensation - Schedule of Share Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Number of Shares
Outstanding at beginning of period (in shares)			2,023,000
Granted (in shares)	0	0	0
Exercised (in shares)			(16,000)
Expired (in shares)			(209,000)
Forfeited (in shares)			(23,000)
Outstanding at end of period (in shares)	1,775,000		1,775,000	2,023,000
Exercisable at end of period (in shares)	1,762,000		1,762,000
Vested and expected to vest at end of period (in shares)	1,774,000		1,774,000
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)			$ 67.68
Granted (in dollars per share)			0
Exercised (in dollars per share)			30.54
Expired (in dollars per share)			73.50
Forfeited (in dollars per share)			63.93
Outstanding at end of period (in dollars per share)	$ 67.38		67.38	$ 67.68
Exercisable at end of period (in dollars per share)	66.97		66.97
Vested and expected to vest at end of period (in dollars per share)	$ 67.36		$ 67.36
Weighted-Average Remaining Years
Outstanding			4 years 1 month 6 days	4 years 7 months 6 days
Exercisable			4 years
Vested and expected to vest			4 years 1 month 6 days
Aggregate Intrinsic Value
Outstanding	$ 2,399		$ 2,399	$ 1,013
Exercisable	2,399		2,399
Vested and expected to vest	$ 2,399		$ 2,399

Employee Benefits and Share-B_8

Employee Benefits and Share-Based Compensation - Schedule of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Number of Shares
Outstanding at beginning of period (in shares)	1,078
Granted (Awarded) (in shares)	1,023
Vested (Released) (in shares)	(297)
Forfeited (in shares)	(130)
Outstanding and unvested at end of period (in shares)	1,674	1,078
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 84.66
Granted (Awarded) (in dollars per share)	40.04
Vested (Released) (in dollars per share)	88.81
Forfeited (in dollars per share)	78.53
Outstanding and unvested at end of period (in dollars per share)	$ 57.13	$ 84.66
Weighted-Average Remaining Years
Outstanding and unvested	1 year 8 months 12 days	1 year 6 months
Aggregate Intrinsic Value
Outstanding and unvested	$ 72,966	$ 40,551

Employee Benefits and Share-B_9

Employee Benefits and Share-Based Compensation - Schedule of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of Shares
Outstanding at beginning of period (in shares) | shares	24
Granted (Awarded) (in shares) | shares	51
Vested (Released) (in shares) | shares	(26)
Outstanding and unvested at end of period (in shares) | shares	49
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 70.96
Granted (Awarded) (in dollars per share) | $ / shares	31.94
Vested (Released) (in dollars per share) | $ / shares	67.32
Outstanding and unvested at end of period (in dollars per share) | $ / shares	$ 31.91

Employee Benefits and Share-_10

Employee Benefits and Share-Based Compensation - Schedule of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of Shares
Outstanding at beginning of period (in shares) | shares	75
Granted (Awarded) (in shares) | shares	177
Vested (Released) (in shares) | shares	(5)
Forfeited (in shares) | shares	(65)
Outstanding and unvested at end of period (in shares) | shares	182
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 127.14
Granted (Awarded) (in dollars per share) | $ / shares	28.67
Vested (Released) (in dollars per share) | $ / shares	157.56
Forfeited (in dollars per share) | $ / shares	122.29
Outstanding and unvested at end of period (in dollars per share) | $ / shares	$ 32.33

Employee Benefits and Share-_11

Employee Benefits and Share-Based Compensation - Schedule of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Sep. 30, 2024 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance (in shares)	9,802
Stock options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance (in shares)	1,775
Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance (in shares)	1,905
Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance (in shares)	3,396
ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance (in shares)	2,726

Restructuring Expenses - Narrat

Restructuring Expenses - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring expense, incurred, net of reversals	$ 600	$ 4,100	$ 5,500
Unpaid balance related to restructuring plan	$ 800	800		$ 8,900
Inventory write-down		$ 5,393	$ 0

Restructuring Expenses - Total

Restructuring Expenses - Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total restructuring expense	$ 620	$ (581)	$ 3,783	$ 5,454
Cost of product and service revenues
Restructuring Cost and Reserve [Line Items]
Total restructuring expense	642	(280)	3,338	102
Research and development
Restructuring Cost and Reserve [Line Items]
Total restructuring expense	(15)	(25)	296	467
Selling, general, and administrative
Restructuring Cost and Reserve [Line Items]
Total restructuring expense	$ (7)	$ (276)	$ 149	$ 4,885